Do analysts rate INAB or TVGN?

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,566.67%. Given Tevogen Bio's higher probable upside, analysts clearly believe Tevogen Bio is more favorable than IN8bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation and earnings, INAB or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.01 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is INAB or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -93.66% -78.41% Tevogen Bio N/A N/A -468.32%

Do analysts prefer INMB or INAB?

INmune Bio currently has a consensus target price of $2.50, indicating a potential upside of 138.10%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts clearly believe INmune Bio is more favorable than IN8bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INMB or INAB more profitable?

INmune Bio's return on equity of -81.71% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -81.71% -62.58% IN8bio N/A -93.66% -78.41%

Do analysts prefer INAB or QNCX?

Quince Therapeutics has a consensus target price of $189.88, indicating a potential upside of 498.41%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than IN8bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quince Therapeutics 2 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.64

Which has preferable valuation and earnings, INAB or QNCX?

IN8bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.01 N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is INAB or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -93.66% -78.41% Quince Therapeutics N/A N/A -133.84%

Do analysts recommend INAB or PMN?

Promis Neurosciences has a consensus target price of $30.50, indicating a potential upside of 827.05%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than IN8bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger earnings & valuation, INAB or PMN?

IN8bio is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.01 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is INAB or PMN more profitable?

IN8bio's return on equity of -93.66% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -93.66% -78.41% Promis Neurosciences N/A -106.96% -87.35%

Do analysts prefer SGMO or INAB?

Sangamo Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 13,413.51%. Given Sangamo Therapeutics' higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than IN8bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SGMO or INAB more profitable?

IN8bio has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. IN8bio's return on equity of -93.66% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% IN8bio N/A -93.66% -78.41%

IN8bio (INAB) Competitors

$0.82 0.00 (-0.04%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$0.84 +0.02 (+1.83%)

As of 11/13/2026 04:10 PM Eastern

Compare

INAB vs. TVGN, INMB, QNCX, PMN, and SGMO

Should you buy IN8bio stock or one of its competitors? IN8bio's main competitors and comparable companies include Tevogen Bio (TVGN), INmune Bio (INMB), Quince Therapeutics (QNCX), Promis Neurosciences (PMN), and Sangamo Therapeutics (SGMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IN8bio compare to Tevogen Bio?

IN8bio (NASDAQ:INAB) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 65.6% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,566.67%. Given Tevogen Bio's higher probable upside, analysts clearly believe Tevogen Bio is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

IN8bio has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Tevogen Bio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.01	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

In the previous week, Tevogen Bio had 1 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for IN8bio. IN8bio's average media sentiment score of 1.18 beat Tevogen Bio's score of 0.46 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Positive
Tevogen Bio	Neutral

Tevogen Bio's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-93.66%	-78.41%
Tevogen Bio	N/A	N/A	-468.32%

Summary

IN8bio beats Tevogen Bio on 9 of the 13 factors compared between the two stocks.

How does IN8bio compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 14.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IN8bio has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	650.16	-$45.93M	-$0.60	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.01	N/A

INmune Bio currently has a consensus target price of $2.50, indicating a potential upside of 138.10%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts clearly believe INmune Bio is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, INmune Bio and INmune Bio both had 2 articles in the media. IN8bio's average media sentiment score of 1.18 beat INmune Bio's score of 0.81 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Positive
IN8bio	Positive

INmune Bio has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

INmune Bio's return on equity of -81.71% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-81.71%	-62.58%
IN8bio	N/A	-93.66%	-78.41%

Summary

INmune Bio beats IN8bio on 9 of the 13 factors compared between the two stocks.

How does IN8bio compare to Quince Therapeutics?

IN8bio (NASDAQ:INAB) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 5.6% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Quince Therapeutics has a consensus target price of $189.88, indicating a potential upside of 498.41%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.64

IN8bio has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

In the previous week, IN8bio and IN8bio both had 2 articles in the media. IN8bio's average media sentiment score of 1.18 beat Quince Therapeutics' score of 0.00 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Positive
Quince Therapeutics	Neutral

IN8bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.01	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Quince Therapeutics' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-93.66%	-78.41%
Quince Therapeutics	N/A	N/A	-133.84%

Summary

Quince Therapeutics beats IN8bio on 7 of the 13 factors compared between the two stocks.

How does IN8bio compare to Promis Neurosciences?

IN8bio (NASDAQ:INAB) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Promis Neurosciences had 3 more articles in the media than IN8bio. MarketBeat recorded 5 mentions for Promis Neurosciences and 2 mentions for IN8bio. IN8bio's average media sentiment score of 1.18 beat Promis Neurosciences' score of 1.12 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Positive
Promis Neurosciences	Positive

IN8bio's return on equity of -93.66% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-93.66%	-78.41%
Promis Neurosciences	N/A	-106.96%	-87.35%

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

IN8bio is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.01	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

IN8bio has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market.

Promis Neurosciences has a consensus target price of $30.50, indicating a potential upside of 827.05%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

IN8bio beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

How does IN8bio compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Sangamo Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 13,413.51%. Given Sangamo Therapeutics' higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IN8bio has lower revenue, but higher earnings than Sangamo Therapeutics. IN8bio is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.01	N/A

In the previous week, IN8bio had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for IN8bio and 0 mentions for Sangamo Therapeutics. IN8bio's average media sentiment score of 1.18 beat Sangamo Therapeutics' score of 0.00 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
IN8bio	Positive

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IN8bio has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. IN8bio's return on equity of -93.66% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
IN8bio	N/A	-93.66%	-78.41%

Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Summary

IN8bio beats Sangamo Therapeutics on 9 of the 14 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.87M	$4.15B	$7.87B	$12.20B
Dividend Yield	N/A	3.62%	2.46%	4.53%
P/E Ratio	-0.81	24.48	34.56	30.65
Price / Sales	N/A	16.43	8.62	5.84
Price / Cash	N/A	26.37	21.93	22.49
Price / Book	0.63	4.00	4.35	3.76
Net Income	-$19.44M	-$22.86M	$3.52B	$390.95M
7 Day Performance	-11.49%	-2.82%	-1.52%	-0.34%
1 Month Performance	-30.80%	-5.39%	-3.54%	-5.79%
1 Year Performance	-48.43%	-1.71%	1.45%	-5.71%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	1.9091 of 5 stars	$0.82 0.0%	N/A	N/A	$8.87M	N/A	N/A	18	Positive News Short Interest Decrease
TVGN Tevogen Bio	1.7198 of 5 stars	$5.73 +2.4%	$100.00 +1,646.4%	N/A	$37.28M	N/A	N/A	18	Upcoming Earnings Gap Down
INMB INmune Bio	2.1318 of 5 stars	$1.32 -4.7%	N/A	N/A	$36.50M	N/A	N/A	21	Analyst Forecast
QNCX Quince Therapeutics	2.1254 of 5 stars	$31.73 flat	$189.88 +498.4%	N/A	$32.27M	N/A	N/A	60	News Coverage
PMN Promis Neurosciences	4.4026 of 5 stars	$3.46 +15.5%	$30.50 +780.5%	N/A	$31.07M	N/A	N/A	11	News Coverage Positive News Earnings Report Analyst Upgrade Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 11/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors

INAB vs. TVGN, INMB, QNCX, PMN, and SGMO

How does IN8bio compare to Tevogen Bio?

Summary

How does IN8bio compare to INmune Bio?

Summary

How does IN8bio compare to Quince Therapeutics?

Summary

How does IN8bio compare to Promis Neurosciences?

Summary

How does IN8bio compare to Sangamo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IN8bio (INAB) Competitors

INAB vs. TVGN, INMB, QNCX, PMN, and SGMO

How does IN8bio compare to Tevogen Bio?

Do insiders and institutionals believe in INAB or TVGN?

Do analysts rate INAB or TVGN?

Which has more risk and volatility, INAB or TVGN?

Which has stronger valuation and earnings, INAB or TVGN?

Does the media refer more to INAB or TVGN?

Is INAB or TVGN more profitable?

Summary

How does IN8bio compare to INmune Bio?

Do institutionals and insiders believe in INMB or INAB?

Which has preferable earnings & valuation, INMB or INAB?

Do analysts prefer INMB or INAB?

Does the media prefer INMB or INAB?

Which has more risk and volatility, INMB or INAB?

Is INMB or INAB more profitable?

Summary

How does IN8bio compare to Quince Therapeutics?

Do insiders & institutionals have more ownership in INAB or QNCX?

Do analysts prefer INAB or QNCX?

Which has more volatility & risk, INAB or QNCX?

Does the media refer more to INAB or QNCX?

Which has preferable valuation and earnings, INAB or QNCX?

Is INAB or QNCX more profitable?

Summary

How does IN8bio compare to Promis Neurosciences?

Does the media prefer INAB or PMN?

Is INAB or PMN more profitable?

Do institutionals and insiders believe in INAB or PMN?

Which has stronger earnings & valuation, INAB or PMN?

Which has more volatility and risk, INAB or PMN?

Do analysts recommend INAB or PMN?

Summary

How does IN8bio compare to Sangamo Therapeutics?

Do analysts prefer SGMO or INAB?

Which has preferable earnings and valuation, SGMO or INAB?

Does the media favor SGMO or INAB?

Do institutionals & insiders hold more shares of SGMO or INAB?

Is SGMO or INAB more profitable?

Which has more volatility and risk, SGMO or INAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools